| 1 |
32926865 | Optimization and validation of a fluorogenic dipeptidyl peptidase 4 enzymatic assay in human plasma. | 2021 Jan 1 |
4 |
| 2 |
33245796 | Pharmacokinetics and safety of evogliptin in hepatically impaired patients. | 2021 Jul |
1 |
| 3 |
33401457 | Evogliptin Suppresses Calcific Aortic Valve Disease by Attenuating Inflammation, Fibrosis, and Calcification. | 2021 Jan 1 |
1 |
| 4 |
33502058 | Cardiovascular safety of evogliptin in patients with type 2 diabetes: A nationwide cohort study. | 2021 Jun |
1 |
| 5 |
33527807 | Clinical Evidence of Evogliptin plus Metformin in Management of Type 2 Diabetes mellitus. | 2021 Feb |
2 |
| 6 |
34304912 | Efficacy and Tolerability of Evogliptin in Patients with Type 2 Diabetes Mellitus: A Systematic Review and Meta-analysis with Bayesian Inference Through a Quality-management System. | 2021 Aug |
2 |
| 7 |
33051573 | Evogliptin, a dipeptidyl peptidase-4 inhibitor, attenuates pathological retinal angiogenesis by suppressing vascular endothelial growth factor-induced Arf6 activation. | 2020 Oct |
1 |
| 8 |
33122892 | Pharmacokinetic/Pharmacodynamic Interaction Between Evogliptin and Pioglitazone in Healthy Male Subjects. | 2020 |
2 |
| 9 |
33489850 | Efficacy and Safety of Novel Dipeptidyl-Peptidase-4 Inhibitor Evogliptin in the Management of Type 2 Diabetes Mellitus: A Meta-Analysis. | 2020 Sep-Oct |
1 |
| 10 |
31890041 | Efficacy and safety of evogliptin in the treatment of type 2 diabetes mellitus in a Brazilian population: a randomized bridging study. | 2019 |
1 |
| 11 |
27761990 | Effects of renal impairment on the pharmacokinetics and pharmacodynamics of a novel dipeptidyl peptidase-4 inhibitor, evogliptin (DA-1229). | 2017 Feb |
4 |
| 12 |
28058750 | Efficacy and safety of adding evogliptin versus sitagliptin for metformin-treated patients with type 2 diabetes: A 24-week randomized, controlled trial with open label extension. | 2017 May |
1 |
| 13 |
28448688 | Efficacy and safety of evogliptin monotherapy in patients with type 2 diabetes and moderately elevated glycated haemoglobin levels after diet and exercise. | 2017 Dec |
1 |
| 14 |
28503751 | In vitro evaluation of potential transporter-mediated drug interactions of evogliptin. | 2017 Sep |
1 |
| 15 |
28806472 | Effects of clarithromycin on the pharmacokinetics of evogliptin in healthy volunteers. | 2017 Dec |
2 |
| 16 |
29061303 | Unique binding mode of Evogliptin with human dipeptidyl peptidase IV. | 2017 Dec 16 |
5 |
| 17 |
27156529 | Evogliptin: a new dipeptidyl peptidase inhibitor for the treatment of type 2 diabetes. | 2016 Jun |
1 |
| 18 |
27570447 | Pharmacokinetic and pharmacodynamic interactions between metformin and a novel dipeptidyl peptidase-4 inhibitor, evogliptin, in healthy subjects. | 2016 |
3 |
| 19 |
25362864 | A randomized, double-blind, placebo-controlled, phase II clinical trial to investigate the efficacy and safety of oral DA-1229 in patients with type 2 diabetes mellitus who have inadequate glycaemic control with diet and exercise. | 2015 Mar |
2 |
| 20 |
26541763 | Evogliptin: First Global Approval. | 2015 Nov |
3 |
| 21 |
25336915 | Multiple-dose pharmacokinetics and pharmacodynamics of evogliptin (DA-1229), a novel dipeptidyl peptidase IV inhibitor, in healthy volunteers. | 2014 |
8 |
| 22 |
22056373 | DA-1229, a novel and potent DPP4 inhibitor, improves insulin resistance and delays the onset of diabetes. | 2012 Jan 2 |
2 |
| 23 |
22943970 | Evaluation of the pharmacokinetics, food effect, pharmacodynamics, and tolerability of DA-1229, a dipeptidyl peptidase IV inhibitor, in healthy volunteers: first-in-human study. | 2012 Sep |
3 |
| 24 |
21570283 | Discovery of DA-1229: a potent, long acting dipeptidyl peptidase-4 inhibitor for the treatment of type 2 diabetes. | 2011 Jun 15 |
1 |